| Title |
Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program
|
|---|---|
| Published in |
BMC Infectious Diseases, June 2014
|
| DOI | 10.1186/1471-2334-14-351 |
| Pubmed ID | |
| Authors |
Amber L Pearson, Giorgi Kvizhinadze, Nick Wilson, Megan Smith, Karen Canfell, Tony Blakely |
| Abstract |
Similar to many developed countries, vaccination against human papillomavirus (HPV) is provided only to girls in New Zealand and coverage is relatively low (47% in school-aged girls for dose 3). Some jurisdictions have already extended HPV vaccination to school-aged boys. Thus, exploration of the cost-utility of adding boys' vaccination is relevant. We modeled the incremental health gain and costs for extending the current girls-only program to boys, intensifying the current girls-only program to achieve 73% coverage, and extension of the intensive program to boys. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 25% |
| United States | 3 | 25% |
| Australia | 1 | 8% |
| Japan | 1 | 8% |
| Unknown | 4 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 75% |
| Scientists | 2 | 17% |
| Practitioners (doctors, other healthcare professionals) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 143 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| Chile | 1 | <1% |
| United Kingdom | 1 | <1% |
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 138 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 28 | 20% |
| Researcher | 26 | 18% |
| Student > Bachelor | 15 | 10% |
| Student > Ph. D. Student | 8 | 6% |
| Student > Doctoral Student | 8 | 6% |
| Other | 22 | 15% |
| Unknown | 36 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 46 | 32% |
| Social Sciences | 10 | 7% |
| Nursing and Health Professions | 8 | 6% |
| Economics, Econometrics and Finance | 7 | 5% |
| Agricultural and Biological Sciences | 6 | 4% |
| Other | 23 | 16% |
| Unknown | 43 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 September 2015.
All research outputs
#2,312,870
of 24,920,664 outputs
Outputs from BMC Infectious Diseases
#658
of 8,386 outputs
Outputs of similar age
#22,510
of 233,559 outputs
Outputs of similar age from BMC Infectious Diseases
#14
of 163 outputs
Altmetric has tracked 24,920,664 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,386 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 233,559 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 163 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.